Compare IGIC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | PCRX |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2019 | 2010 |
| Metric | IGIC | PCRX |
|---|---|---|
| Price | $24.24 | $22.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $28.00 | ★ $35.33 |
| AVG Volume (30 Days) | 50.4K | ★ 761.1K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $0.13 | $9.77 |
| Revenue Next Year | $2.54 | $9.71 |
| P/E Ratio | ★ $9.05 | $137.50 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $20.82 | $18.80 |
| 52 Week High | $27.63 | $27.99 |
| Indicator | IGIC | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 50.88 |
| Support Level | $22.68 | $20.41 |
| Resistance Level | $24.26 | $23.82 |
| Average True Range (ATR) | 0.84 | 1.02 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 30.19 | 59.16 |
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.